The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


FDA approves Kite?s Car T therapy Yescarta for B-Cell Lymphoma.....           Alnylam, Vir to jointly advance RNAi therapeutics for infectious diseases.....           Boehringer Ingelheim partners with TARGET to progress NASH research.....           Biosimilar threat starts to creep up on Roche as Rituxan loses ground.....           With FDA panel backing, Novo Nordisk prepares for semaglutide's potential launch.....           Allergan's stock-price struggles sure to trigger breakup questions: analyst.....           Reckitt Benckiser, eyeing Pfizer OTC, carves out consumer health unit in reorganization.....           Teva seeks FDA approval for migraine drug fremanezumab.....           With 'Dear Scientist' campaign from BG BrandLab, Pfizer keeps researchers in the spotlight.....           Outcome Health launches internal probe, offers client audits after WSJ report.....           Padding its lung cancer lead, Merck's Keytruda helped PD-L1 patients live 30 months longer.....           AstraZeneca lobbies for personalized asthma care with new visual snapshot tool.....           More pharma friends in high places? Ex-Lilly boss Alex Azar up for HHS chief.....           AstraZeneca's Lynparza ups the ante at the PARP table with FDA's speedy breast cancer review.....           Bristol-Myers' Opdivo gets into high gear for new melanoma approval.....           Veterans' lawsuit claims Big Pharma bribes in Iraq helped finance terrorism.....           Troubled Orexigen looks for a buyer, but will anyone want Contrave?.....           Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod.....           Amneal to acquire Impax to expand generics business in US.....           US FDA accepts sBLA for Imfinzi in locally advanced and unresectable NSCLC.....           Ignyta?s Entrectinib gets EMA prime designation for NTRK fusion-positive solid tumors.....           Takeda, HemoShear collaborate to develop drugs for liver diseases.....           Generics squeeze forces Novartis Colorado plant to close, imperiling 450 jobs.....           GlaxoSmithKline wins first-ever nod for blockbuster vaccine prospect Shingrix.....           Johnson & Johnson says Puerto Rico plants 'fared well' in Maria but 'intermittent' shortages possible.....           Facing antitrust lawsuit, J&J's Remicade stands firm against biosimilar competition in Q3.....           Bisaro steers Impax to $6.4B Amneal merger, creating fifth-largest U.S. generics company.....           Despite notable failures, cancer vaccines are poised for a leap onto the market: expert.....           J&J prevails in first talc appeal as judges vacate $72M verdict.....           US federal judge invalidates Allergan patents on Restasis.....           US FDA accepts BMS? application for Opdivo (nivolumab) in patients with resected high-risk advanced melanoma.....           Pfizer?s lung cancer drug lorlatinib succeeds in phase 2 trial.....           Exelixis? liver cancer drug cabozantinib meets primary end point in phase 3 trial.....           FDA panel backs approval of Aerie?s Rhopressa for glaucoma treatment.....           UK?s NICE makes Nivolumab available for head and neck cancer patients.....           miRagen Therapeutics reports positive clinical data of MRG-106 in patients with mycosis fungoides form of cutaneous T-cell lymphoma.....           Merck targets high-risk military veterans for hepatitis C lessons.....           Johnson & Johnson's Stelara, pressured on all sides, breaks into adolescent psoriasis market.....           'Sham' or legit? Texas judge set to weigh in on Allergan's tribal patent deal.....           Activist hedge fund angles for Shire breakup to revive struggling shares.....           McKesson, Cardinal and AmerisourceBergen scrutinized over opioid arm-twisting.....           FDA digs into semaglutide CV benefits, eye safety ahead of Novo Nordisk drug's panel review.....           Reckitt Benckiser's still keen on a Pfizer OTC buy. But can it afford one?.....           Allergan loses Restasis patent protections in federal court decision.....           Alexa-enabled diabetes manager, complete with foot-scanning scale, nabs Merck prize.....           Moleculin to collaborate with University of Bergen for immune stimulation drug.....           FiercePharmaAsia?China?s new drug policy guidelines, Mylan-Biocon?s Neulasta biosim, C-Bridge hire.....           Did Avanir overmarket its brain drug to the elderly?.....           Allergan settles Restasis litigation with Pfizer's InnoPharma as backlash mounts over tribal patent deal.....           NICE flip-flops to back Bristol-Myers' Opdivo in head and neck cancer despite data 'uncertainties'.....           As Taltz growth stalls, Lilly looks ahead to psoriatic arthritis expansion.....           FDA panel supports Spark Therapeutics gene therapy approval for rare form of blindness.....           Human clinical trial commences for first leprosy vaccine candidate.....           Advice for pharma in payer marketing? Ramp up digital, study finds.....           Ebola vaccines from GlaxoSmithKline, Merck elicit yearlong response, study finds.....           NICE expands Bayer's Stivarga prospects with move from CDF.....           With a year left before generics hit, Pfizer nabs FDA approval for new-and-improved Lyrica.....           No sale for Novartis' $14B Roche stake, but the revamp's not done.....           Sanofi to invest €170m for expansion of French vaccine manufacturing facility.....           Lupin buys Symbiomix to expand women?s health specialty business.....           Janssen submits NDA to FDA for apalutamide to treat non-metastatic castration-resistant prostate cancer.....           Ardelyx's phase 3 study of Tenapanor for IBS-C meets primary endpoint.....           Don't give up on tough-to-treat depression, Janssen R&D says in new video push.....           Heart disease tears couples apart in Novo Nordisk's new awareness ads.....           New Neurocrine, Teva meds win doctors' praise, fueling bigger sales expectations.....           Krystexxa shows signs of life as Horizon keeps pushing sales force expansion.....           Opposite (side) effect? More red flags in DTC ads actually boost patient confidence.....           Hot to trot with Zilretta, Flexion rolls $100M-plus stock offering to fund the launch.....           Rumored HHS candidate Gottlieb says he's 'most effective' at FDA. Pharma might agree.....           Will 5% be the next price-hike ceiling? California law adds to industry pressure: analyst.....           Pfizer considers sale of consumer healthcare business.....           Moffitt researchers discover new targets for approved cancer drug.....           Gilotrif gets FDA priority review for uncommon EGFR mutations in advanced NSCLC.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
Forthcoming events

APS Advances in Amorphous Design, Control and Delivery of Amorphous and Co-amorphous Pharmaceutical Materials
Tuesday 3 October 2017 at Friends House, London

A one day meeting will be held on Tuesday 3rd October 2017 in London to highlight the significant advances in the design, control and production of amorphous and co-amorphous materials since the last highly successful APS amorphous meeting in 2014. The meeting is organised by the APS Materials Science Focus Group.

For more information and to register, click here

APS Developing Clinically Relevant Dissolution Specifications for Oral Drug Products - Industrial and Regulatory Perspectives
APS Biopharmaceutics and Regulatory Sciences Joint Meeting
Tuesday 7 November 2017 at Friends House, London

Contribute to the longer-term goal of establishing a regulatory framework to guide the development of Clinically Relevant Dissolution Specifications for Oral Drug Products. The meeting is organised by the APS Biopharmaceutics and Regulatory Sciences Focus Groups.

For more information and to register, click here

 
 
APS PharmSci 2018 Conference

Date: Friday 7 September 2017
Location: Hilton Hotel, Glasgow

The conference in 2018, will be held in Glasgow, linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference which will take place in the city from the 2nd to the 6th September. The one day APS conference will have its usual focus on the pharmaceutical sciences with the theme and session have been selected to fit in with the two of the topics of the FIP conference:

  • From bench to bedside: Advancing pharmaceutical care
  • Targeting special interests

We are pleased to announce this year’s science chair is Dr Claire Thompson.

I am delighted to be the Science Chair of the 2018 PharmSci conference which will be held in Glasgow on 7th Sep. The theme of the event is “The Science of Differentiated Medicines” and will include sessions on:

  • Age-related medicines
  • Medicines and diagnostics for the developing world
  • Targeted therapies
  • Medicines for specialised populations

The conference will delve into the science which underpins targeting therapies for cancer, formulations for paediatric and geriatric medicines, and the innovation required to develop and deliver healthcare solutions for the poorest countries in the world. I look forward to seeing you in Glasgow for what will be a fantastic event!

Claire is an award-winning scientist and innovator with more than 15 years’ experience in the Pharmaceutical Industry spanning the large multi-nationals GlaxoSmithKline and Pfizer, virtual and Contract Research Organisations. She is the Founder of Agility Health Tech, a consulting and communications firm which works with organisations across the healthcare space to advance their products and raise their profile. She is also Deputy Chief Scientist of the Royal Pharmaceutical Society.

Having taken a range of therapeutic products through clinical Phases 1 to 3, she thrives on translating innovative technologies into healthcare products and shaping technical and organisational strategies. She was honoured with the Royal Pharmaceutical Society’s Pharmaceutical Science Award in 2015, and the Academy of Pharmaceutical Sciences’ Medal in 2016.

Before founding Agility Health Tech, she was Head of Research and Development with Oxford PharmaScience, an AIM-listed virtual Pharmaceutical company identified as one of the "Top 10 Emerging Technology Companies 2012". Here she evaluated and identified new technologies for in-licensing, transferring them from universities/companies and directed the scale-up through CROs/CMOs in adherence to EU and FDA cGMP requirements. She also engaged with investors, manufacturing and licensing partners to build capital, product supply and revenue respectively.

Prior to this, Claire was Associate Director at Molecular Profiles (now Juniper Pharmaceuticals) and spent 7˝ years at GlaxoSmithKline and Pfizer developing novel molecules and formulations for therapeutic areas such as asthma, cancer, HIV, insomnia, malaria and pain.

Claire was Chief Scientist of the Academy of Pharmaceutical Sciences from 2012 -2016. She holds Honorary Senior Lectureships in the College of Medical & Dental Sciences at the University of Birmingham and the School of Pharmacy at University College London. She holds a PhD from School of Pharmacy, University of Nottingham, and a BSc in Biochemistry from the University of St. Andrews.

 
 

Reflections on APS PharmSci 2017 Conference

Date: 5 - 7 September 2017
Location: De Havilland Campus, University of Hertfordshire, Hatfield
Conference Chair: Professor Abdul Basit (University College London)
Theme: Pharmaceutical Science without Borders


A very successful 3-day conference provided an excellent interactive face to face forum for exchange of knowledge and sharing learnings and experiences in many aspects of the pharmaceutical sciences. With 80+ inspiring speakers and over 390 delegates joined together from academia, the Pharmaceutical Industry, and service companies. During the sessions, there was a steady flow of discussion which continued into the breaks and around the exhibition stands and posters.
 

Young pharmaceutical scientists had their first opportunity to present either a poster or podium presentation (or indeed both!) which is a major strength of APS PharmSci.

 

Read more, as Linda Hakes (Retiring APS Chair) and Mark McAllister (APS Chair) talk about their experiences at this year’s PharmSci.

Latest News
RPS Excellence in Pharmaceutical Science Excellence in Pharmaceutical Science Award
WEDNESDAY, 10 MAY 2017
Excellence in Pharmaceutical Science recognises those who have delivered proactive and innovative projects and initiatives that lead the way in pharmaceutical science. . The nominee should have demonstrated excellence in pharmaceutical science, by showing innovation and initiative, and contributing to a project which has had an impact on the improvement of pharmaceutical science.. To download the nomination form, please visit us online here:. https://www.rpharms.com/events/rps-awards. To be considered for the nomination the nominee must cover all aspects in the criteria. Completed nomination forms should be sent to events@rpharms.com by Monday 29 May 5pm..
Applications invited for the 2017 Royal Pharmaceutical Society Science Award
TUESDAY, 9 MAY 2017
Applications are invited for the 2017 Royal Pharmaceutical Society Science Award. The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the RPS Award Lecture on their work at the Academy of Pharmaceutical Sciences International PharmSci Conference meeting on Thursday 7th September 2017.. Applications are welcome from scientists world-wide who are working in a pharmaceutical or allied discipline in industry or academia. With up to 10 years experience at post-doctoral level in September 2017, applicants must have a proven record of independent research and published work that shows outstanding promise. . Applicants are invited to submit the following details by 31st May 2017: . · Full CV detailing personal information, past and present appointments, research responsibilities and published work. . · List of research students who have worked for the applicant and their thesis titles and dates, plus any other instances of research collaborations . · Details of research grants awarded and the candidate’s role . · Invitations to speak at conferences in the UK and overseas, lecture or symposium titles and names of awards . · A brief resume of two pages should also be submitted with the CV, indicating discoveries made (please note copies of publications are not required). . Submissions should be sent to: evidence@rpharms.com or by post to: Rachel Joynes, Head of Research Royal Pharmaceutical Society 66-68 East Smithfield London E1W 1AW. .
APS 8th International PharmSci Conference 2017 Call for Abstracts
THURSDAY, 12 JANUARY 2017
. 'Pharmaceutical Sciences Without Borders’. Tuesday 5 – Thursday 7 September 2017 De Havilland Campus of the University of Hertfordshire in Hatfield. Call for Abstracts. Abstracts are invited for posters for APS International PharmSci 2017. This is one of the most exciting parts of the conference as it represents the presentation of the very latest pharmaceutical science research.. Abstracts on any aspect of the Pharmaceutical Sciences are welcomed and those with a particular emphasis on the theme of this year’s Conference, 'Pharmaceutical Sciences Without Borders’ are particularly appreciated. Details of the various subject categories, an abstract template and details of the entry process can be found here:. http://www.ukpharmsci.org/abstracts/default.asp. Please ensure abstracts are submitted online and comply with the Abstract Submission Template. Please note one or two page abstracts are welcomed providing they follow the template.. There will be prizes awarded for winning posters on each day of the Conference and authors of abstracts of particular interest will be invited to give podium presentations (15min). This is an excellent chance to get your science recognised at the UK’s premier Pharmaceutical Science Conference. The closing date for abstract submission is Friday 17th March 2017.. Abstracts will be made available to Conference registrants when the abstract author has registered for the Conference. We also intend to publish the abstracts in a journal after the Conference and authors not wishing to take up this opportunity are requested to indicate this where indicated when they submit their abstract.. Entrants in the Analytical Chemistry category may be eligible for the Geoffrey Phillips Analytical Science Award, subject to meeting the criteria, awarded by the Joint Pharmaceutical Analysis Group (JPAG). The purpose of the Award is to encourage the advancement of pharmaceutical analysis and to recognise contributions of emerging scientists reporting wholly or mainly their own work. The winner receives a prestigious award with a bursary of up to £1000 to attend a conference relevant to their area of interest.. http://www.jpag.org/?&sid=20170112135948802597&p=awards#award. Exhibitor Opportunities. The conference includes a large pharmaceutical sciences exhibition, which is open to large pharma companies, small and medium size enterprises (SMEs), contract research organisations (CROs) and technology suppliers. With one of the largest gatherings of pharmaceutical scientists in the UK, the conference offers a great opportunity to showcase your company.. For more information please contact us: info@apsgb.org or 0116 274 7351. .
APS Fellowships Announcement 2017
WEDNESDAY, 2 NOVEMBER 2016
Do you know someone who has made a significant contribution to Pharmaceutical Science?. The APS is calling for nominations of candidates to become Fellow or Eminent Fellow of the Academy of Pharmaceutical Sciences.. Nominees for Fellowship must be a member of APS (for at least one year) and have a proven track record in pharmaceutical science, as demonstrated by at least 15 peer-reviewed publications, patents or equivalent. This would include significant contributions to the development of products or medical devises within the pharmaceutical industry. Nominees must also have demonstrated leadership and peer recognition through invited lectures, conference leadership, mentoring of young scientists etc. Candidates may self-nominate and nominations must consist of a one-page summary of achievements accompanies by a CV.. Nominations for Eminent Fellowship may be submitted by any member of APS but self-nominations are not accepted. Nominees for Eminent Fellowship must have international recognition for their advocacy of science and have demonstrated leadership at international level. Nominations should consist of a one-page summary of achievements and an explanation of why Eminent Fellowship is justified, and be accompanied by a CV.. Nominations should be sent to info@apsgb.org by 1 March 2017.

Follow us
 
Upcoming Events
APS Developing Clinically Relevant Dissolution Specifications for Oral Drug Products - Industrial and Regulatory Perspectives
APS Biopharmaceutics and Regulatory Sciences Joint Meeting

7 November 2017
Pharma Integrates 2017
15 - 16 November 2017
Antimicrobial Resistance: Meeting the Challenge
Joint meeting with the Society for Applied Microbiology

23 November 2017
APS Developability Workshop
30 - 31 January 2018
APS Current Regulatory trends and updates in parenteral drug product development
20 - 21 March 2018
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.